Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to “Work it Out”?

E-ISSN： 1873-4286|20|24|3863-3874

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-01, pp. : 3863-3874

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)

By Blumenschein George

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1802-1811

Springer Publishing Company

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)

By Alvarez-Fernandez Carlos Perez-Arnillas Quionia Ruiz-Echeverria Lucrecia Rodriguez-Rubi David Sanchez-Lorenzo Luisa Li-Torres Walter Izquierdo-Manuel Marta Berros Jose Luque-Cabal Maria Jimenez-Fonseca Paula Villanueva-Palicio Noemi Esteban-Gonzalez Emilio

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 377-381

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 12-28

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 67-73

Bentham Science Publishers

Access to resources Recommend Favorite